Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer
19 août 2024 08h45 HE
|
Sonnet BioTherapeutics Holdings, Inc.
Preclinical data has demonstrated the potential of SON-1210, the first albumin-binding bifunctional IL-12/IL-15 fusion protein, for solid tumor immunotherapy An Innovative Immuno Oncology...
Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
14 août 2024 08h35 HE
|
Sonnet BioTherapeutics Holdings, Inc.
Ongoing progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC) Partnership efforts to support initiation of a Phase 2 clinical...
Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study
24 juil. 2024 08h30 HE
|
Sonnet BioTherapeutics Holdings, Inc.
Data indicates that SON-080 was well-tolerated at both doses, with no evidence of a pro-inflammatory cytokine responsePain and quality of life survey results suggest the potential for rapid...
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
20 juin 2024 08h30 HE
|
Sonnet BioTherapeutics Holdings, Inc.
PRINCETON, N.J., June 20, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic...
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
13 juin 2024 08h00 HE
|
Sonnet BioTherapeutics Holdings, Inc.
Sonnet discovered and characterized a modified version of Interleukin-18 (IL-18Binding Protein Resistant or IL-18BPR) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with...
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
28 mai 2024 08h00 HE
|
Sonnet BioTherapeutics Holdings, Inc.
PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic...
Sonnet BioTherapeutics Holdings Announces Merger Closing
01 avr. 2020 17h53 HE
|
Sonnet BioTherapeutics Holdings, Inc.
- Trading under “SONN” on the Nasdaq Capital Market to begin April 2, 2020- Closed $19 million financing PRINCEON, N.J., April 01, 2020 (GLOBE NEWSWIRE) -- Sonnet BioTherapuetics Holdings, Inc.,...
Chanticleer Holdings Announces 1-for-26 Reverse Stock Split
31 mars 2020 16h06 HE
|
Chanticleer Holdings, Inc.
Nasdaq approves continued listing of Sonnet BioTherapeutics following closing of mergerMerger transaction expected to close on April 1, 2020Trading under “SONN” expected to begin April 2, 2020 ...
Chanticleer Holdings Announces 1:1 Distribution Ratio for Spin-Off and Provides Corporate Update
24 mars 2020 17h38 HE
|
Chanticleer Holdings, Inc.
CHARLOTTE, N.C., March 24, 2020 (GLOBE NEWSWIRE) -- Chanticleer Holdings, Inc. (Nasdaq: BURG) (the “Company” or “Chanticleer”), owner, operator and franchisor of multiple nationally-recognized...
Chanticleer Holdings Announces Results of Shareholder Vote
19 mars 2020 08h30 HE
|
Chanticleer Holdings, Inc.
CHARLOTTE, N.C., March 19, 2020 (GLOBE NEWSWIRE) -- Chanticleer Holdings, Inc. (NASDAQ:BURG) (“Chanticleer” or the “Company”), owner, operator, and franchisor of multiple nationally recognized...